Zhuang Wei, Fan Zheng, Chu Yanqi, Wang Haizheng, Yang Ying, Wu Li, Sun Nan, Sun Ge, Shen Yuqiao, Lin Xiaolan, Guo Guiming, Xi Shengyan
Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, China.
Department of Clinical Pharmacy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Front Pharmacol. 2020 Jul 17;11:1066. doi: 10.3389/fphar.2020.01066. eCollection 2020.
Coronavirus Disease 2019 (COVID-19) is an emerging and rapidly evolving disease, with no recommended effective anti-coronavirus drug treatment. Traditional Chinese Patent Medicines (CPMs) have, however, been widely used to treat COVID-19 in China, and a number of clinical practice results have shown them to have a significant role in its treatment. Consequently, numerous guidelines and expert consensus have recommended the use of CPMs to treat COVID-19.
The objectives of this review are to provide up-to-date information on the pharmacology and clinical research on CPMs in the treatment of COVID-19, discuss the research findings, and to better guide clinical application and scientific research on CPMs in the treatment of COVID-19.
The frequencies of CPM recommendations by guidelines and expert consensus for treatment of COVID-19 in China were ranked. This report identifies the top 10 CPMs, which include Huoxiang Zhengqi capsule (HXZQC), Lianhua Qingwen capsule (LHQWC), Jinhua Qinggan granule (JHQGG), Shufeng Jiedu capsule (SFJDC), Tanreqing injection (TRQI), Xiyanping injection (XYPI), Xuebijing injection (XBJI), Shenfu injection (SFI), Shengmai injection (SMI), and Angong Niuhuang pill (AGNHP). Relevant studies from 2000 to 2020 on these top 10 CPMs, covering usage, dosage, mechanism, curative effect, and precautions, were collected from pharmacopoeia, reports, and theses library and digital databases (including PubMed, CNKI, Google Scholar, Web of Science, and Elsevier).
The properties of the top 10 CPMs included antiviral, antibacterial, anti-inflammatory, antipyretic and analgesic, anti-acute lung injury, anti-shock, immune regulation, and enhancement of pulmonary function. In addition, clinical research results and Chinese treatment data showed that the CPMs had good therapeutic efficacy in the treatment of COVID-19, and adverse reactions were minimal.
Knowledge of the characteristics of the top 10 CPMs and precautions that should be taken may help clinicians to rationally improve therapeutic efficacy, and promote the role of Chinese Medicine in the control of the COVID-19 global epidemic.
2019冠状病毒病（COVID-19）是一种新出现且迅速演变的疾病，目前尚无推荐的有效抗冠状病毒药物治疗方法。然而，中成药在中国已被广泛用于治疗COVID-19，多项临床实践结果表明它们在治疗中发挥了重要作用。因此，众多指南和专家共识推荐使用中成药治疗COVID-19。
本综述的目的是提供有关中成药治疗COVID-19的药理学和临床研究的最新信息，讨论研究结果，并更好地指导中成药治疗COVID-19的临床应用和科学研究。
对中国指南和专家共识中推荐用于治疗COVID-19的中成药频率进行排名。本报告确定了排名前十的中成药，包括藿香正气胶囊（HXZQC）、连花清瘟胶囊（LHQWC）、金花清感颗粒（JHQGG）、疏风解毒胶囊（SFJDC）、痰热清注射液（TRQI）、喜炎平注射液（XYPI）、血必净注射液（XBJI）、参附注射液（SFI）、生脉注射液（SMI）和安宫牛黄丸（AGNHP）。从药典、报告、论文库和数字数据库（包括PubMed、CNKI、谷歌学术、科学网和爱思唯尔）收集了2000年至2020年关于这十种排名靠前的中成药的相关研究，内容涵盖用法、用量、作用机制、疗效和注意事项。
排名前十的中成药的特性包括抗病毒、抗菌、抗炎、解热镇痛、抗急性肺损伤、抗休克、免疫调节和增强肺功能。此外，临床研究结果和中医治疗数据表明，中成药在治疗COVID-19方面具有良好的治疗效果，且不良反应极小。
了解排名前十的中成药的特性以及应采取的注意事项，可能有助于临床医生合理提高治疗效果，并促进中医药在控制COVID-19全球疫情中的作用。
